Leveraging PK/PD Modeling & AI/ML Capabilities to Optimize Antibody Properties & Payload Selection for Best-in-Class ADC Discovery & Development

• Utilizing PK/PD modeling to understand ADC and payload distribution in-circulation and in-tumor tissue to optimize payload discovery and selection
• Applying AI/ML to tumor target distribution data to inform ideal antibody properties and maximize ADC therapeutic index
• Contextualizing best-in-class ADC development through discovery and preclinical profile of PBX-004

Speakers:

Doo Young Jung

Founder & Chief Executive Officer

Pinotbio